{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04892017",
            "orgStudyIdInfo": {
                "id": "DCC-3116-01-001"
            },
            "organization": {
                "fullName": "Deciphera Pharmaceuticals LLC",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Phase 1/2 Study of DCC-3116 in Patients With RAS/MAPK Pathway Mutant Solid Tumors",
            "officialTitle": "A Phase 1/2, First-in-Human Study of DCC-3116 as Monotherapy and in Combination With RAS/MAPK Pathway Inhibitors in Patients With Advanced or Metastatic Solid Tumors With RAS/MAPK Pathway Mutations",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-phase-study-of-dcc-in-patients-with-ras-mapk-pathway-mutant-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-06-15",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-08",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-08",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-05-06",
            "studyFirstSubmitQcDate": "2021-05-13",
            "studyFirstPostDateStruct": {
                "date": "2021-05-19",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-17",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-18",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Deciphera Pharmaceuticals LLC",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a Phase 1/2, multicenter, open label, first in human (FIH) study of DCC-3116 as monotherapy, and in combination with trametinib, binimetinib, or sotorasib in patients with advanced or metastatic solid tumors with RAS/MAPK pathway mutation. The study consists of 2 parts, a dose-escalation phase, and an expansion phase."
        },
        "conditionsModule": {
            "conditions": [
                "Non-Small Cell Lung Cancer",
                "Advanced Solid Tumor",
                "Metastatic Solid Tumor"
            ],
            "keywords": [
                "KRAS G12C",
                "DCC-3116"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 173,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Dose Escalation (Part 1, Cohort A Monotherapy)",
                    "type": "EXPERIMENTAL",
                    "description": "DCC-3116 tablets in escalating dose cohorts given orally twice daily (BID) in 28-day cycles as monotherapy (single agent). If no DLT in 3 participants or 1 DLT/6 participants is observed, dose escalation may continue to the next planned dose cohort.",
                    "interventionNames": [
                        "Drug: DCC-3116"
                    ]
                },
                {
                    "label": "Dose Escalation (Part 1, Cohort B Combination)",
                    "type": "EXPERIMENTAL",
                    "description": "Upon determination of the RP2D/MTD single agent, DCC-3116 will be dosed in combination with trametinib.\n\nEscalation Cohort B combination closed on January 8, 2024.",
                    "interventionNames": [
                        "Drug: DCC-3116",
                        "Drug: Trametinib"
                    ]
                },
                {
                    "label": "Dose Escalation (Part 1, Cohort C Combination)",
                    "type": "EXPERIMENTAL",
                    "description": "Upon determination of the RP2D/MTD single agent, DCC-3116 will be dosed in combination with binimetinib.\n\nEscalation Cohort C combination closed on January 8, 2024.",
                    "interventionNames": [
                        "Drug: DCC-3116",
                        "Drug: Binimetinib"
                    ]
                },
                {
                    "label": "Dose Escalation (Part 1, Cohort D Combination)",
                    "type": "EXPERIMENTAL",
                    "description": "Upon determination of the RP2D/MTD single agent, DCC-3116 will be dosed in combination with sotorasib.",
                    "interventionNames": [
                        "Drug: DCC-3116",
                        "Drug: Sotorasib"
                    ]
                },
                {
                    "label": "Expansion Cohorts 1, 2, 3 and 4 (Part 2)",
                    "type": "EXPERIMENTAL",
                    "description": "Expansion Cohorts 1, 2, 3 and 4 DCC-3116 combinations will not open for enrollment.",
                    "interventionNames": [
                        "Drug: DCC-3116"
                    ]
                },
                {
                    "label": "Expansion Cohort 5 (Part 2)",
                    "type": "EXPERIMENTAL",
                    "description": "DCC-3116 tablets orally given in combination with sotorasib in 28-day cycles to evaluate safety and preliminary efficacy of participants with NSCLC (with a documented mutation in KRAS G12C).",
                    "interventionNames": [
                        "Drug: DCC-3116",
                        "Drug: Sotorasib"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "DCC-3116",
                    "description": "Oral Tablet Formulation",
                    "armGroupLabels": [
                        "Dose Escalation (Part 1, Cohort A Monotherapy)",
                        "Dose Escalation (Part 1, Cohort B Combination)",
                        "Dose Escalation (Part 1, Cohort C Combination)",
                        "Dose Escalation (Part 1, Cohort D Combination)",
                        "Expansion Cohort 5 (Part 2)",
                        "Expansion Cohorts 1, 2, 3 and 4 (Part 2)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Trametinib",
                    "description": "Oral Tablet Formulation",
                    "armGroupLabels": [
                        "Dose Escalation (Part 1, Cohort B Combination)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Binimetinib",
                    "description": "Oral Tablet Formulation",
                    "armGroupLabels": [
                        "Dose Escalation (Part 1, Cohort C Combination)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Sotorasib",
                    "description": "Oral Tablet Formulation",
                    "armGroupLabels": [
                        "Dose Escalation (Part 1, Cohort D Combination)",
                        "Expansion Cohort 5 (Part 2)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of Adverse Events",
                    "description": "Identify the observed adverse events, serious adverse events associated with DCC-3116 as monotherapy and in combination with trametinib, binimetinib, or sotorasib.",
                    "timeFrame": "Approximately 24 months"
                },
                {
                    "measure": "Maximum tolerated dose (MTD) (Escalation Phase)",
                    "description": "Identify the dose-limiting toxicities for each dose level tested and determine the maximum tolerated dose/recommended Phase 2 doses of DCC-3116 as monotherapy and in combination with trametinib, binimetinib, or sotorasib.",
                    "timeFrame": "Approximately 18 months"
                },
                {
                    "measure": "Objective response rate (ORR) (Expansion Phase)",
                    "description": "Proportion of participants who achieve CR or PR per RECIST v1.1.",
                    "timeFrame": "Approximately 24 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Duration of response (DoR)",
                    "description": "DoR is defined as the time interval from the time that the measurement criteria are first met for CR or PR (whichever is first recorded) until the first date that the progressive disease is objectively documented or death, whichever occurs first.",
                    "timeFrame": "Approximately 24 months"
                },
                {
                    "measure": "Disease Control Rate (DCR)",
                    "description": "The DCR is defined as the proportion of participants who achieve CR, PR, or stable disease (SD) at the specified time point per RECIST v1.1.",
                    "timeFrame": "Approximately 24 months"
                },
                {
                    "measure": "Time to response",
                    "description": "Time to response is defined as the time from initiation of treatment until the first assessment demonstrating CR or PR per RECIST v1.1.",
                    "timeFrame": "Approximately 24 months"
                },
                {
                    "measure": "Progression-free survival (PFS)",
                    "description": "PFS is defined as the time from initiation of treatment until documented disease progression per RECIST v1.1 or death, whichever occurs first.",
                    "timeFrame": "Approximately 24 months"
                },
                {
                    "measure": "Maximum observed concentration (Cmax)",
                    "description": "Measure the maximum observed concentration of DCC-3116 (single-agent and combinations).",
                    "timeFrame": "Predose and up to 12 hours postdose"
                },
                {
                    "measure": "Time to maximum observed concentration (Tmax)",
                    "description": "Measure the time to maximum plasma concentration of DCC-3116 (single-agent and combinations).",
                    "timeFrame": "Predose and up to 12 hours postdose"
                },
                {
                    "measure": "Minimum observed concentration (Cmin)",
                    "description": "Measure the minimum observed concentration of DCC-3116 (single-agent and combinations).",
                    "timeFrame": "Predose and up to 12 hours postdose"
                },
                {
                    "measure": "Area under the concentration-time curve (AUC)",
                    "description": "Measure the AUC of DCC-3116 (single-agent and combinations).",
                    "timeFrame": "Predose and up to 12 hours postdose"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Male or female participants \u226518 years of age\n2. Dose Escalation Phase (Part 1):\n\n   Escalation Cohort B combination with trametinib and Cohort C combination with binimetinib closed on January 8, 2024.\n   1. Participants must have a pathologically confirmed diagnosis of an advanced or metastatic solid tumor with a documented RAS, NF1, or RAF mutations. A molecular pathology report documenting mutational status of RAS, NF1, or RAF must be available.\n   2. Progressed despite standard therapies, and received at least 1 prior line of anticancer therapy.\n\n      * Participants with a documented mutation in BRAF V600E or V600K must have received approved treatments known to provide clinical benefit prior to study entry.\n   3. Participants enrolled in the DCC-3116 and sotorasib cohort (Cohort D) must have a KRAS G12C mutation.\n3. Dose Expansion Phase (Part 2):\n\n   Expansion Cohorts 1, 2, 3 and 4 combinations will not open for enrollment.\n\n   Cohort 5: Patients with KRAS G12C mutant NSCLC\n   * Pathologically confirmed NSCLC with a documented mutation in KRAS G12C.\n   * Received at least 1 prior line but no more than 3 prior lines of systemic therapy in the advanced or metastatic setting.\n   * Have not received prior sotorasib or other KRAS G12C inhibitor therapy.\n4. Must provide a fresh tumor biopsy from a primary or metastatic cancer lesion that can be biopsied with acceptable risk as determined by the Investigator, and archival tumor tissue sample, if available. If a fresh tumor biopsy is not possible, then an archival tumor tissue sample must be provided.\n5. Eastern Cooperative Oncology Group (ECOG) score of 0 to 2 (Dose Escalation) or 0 to 1 (Dose Expansion) at Screening\n6. Adequate organ function and bone marrow function.\n7. If a female of childbearing potential must have a negative pregnancy test prior to enrollment and agree to follow the contraception requirements.\n8. Male participants must agree to follow contraception requirements.\n9. Must provide signed consent to participate in the study and is willing to comply with study-specific procedures.\n\nExclusion Criteria:\n\n1. Must not have received the following within the specified time periods prior to the first dose of study drug:\n\n   1. Prior therapies (anticancer or therapies given for other reasons) that are known strong or moderate inhibitors or inducers of CYP3A4 or P-gp including certain herbal medications (e.g., St. John's Wort): 14 days or 5\u00d7 the half-life of the medication (whichever is longer)\n   2. All other prior anticancer therapies or any therapy that is investigational for the participant's condition with a known safety and PK profile: 14 days or 5\u00d7 the half-life of the medication (whichever is shorter)\n   3. Investigational therapies with unknown safety and PK profile: 28 days. If there is enough data on the investigational therapy to assess the risk for drug-drug interactions and late toxicities of prior therapy as low, the Sponsor's Medical Monitor may approve a shorter washout of 14 days\n   4. Grapefruit or grapefruit juice: 14 days\n2. Have not recovered from all toxicities from prior therapy according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE).\n3. Presence or history of central nervous system (CNS) metastases or leptomeningeal disease, with some exceptions\n4. New York Heart Association Class III or IV heart disease, active ischemia, or any other uncontrolled cardiac condition such as angina pectoris, clinically significant cardiac arrhythmia requiring therapy, uncontrolled hypertension, congestive heart failure, or myocardial infarction within 6 months prior to the first dose of study drug.\n5. Prolongation of the QT interval corrected by Fridericia's formula (QTcF) based on repeated demonstration of QTcF \\>450 ms in males or \\>470 ms in females at screening, or history of long QT syndrome.\n6. Left ventricular ejection fraction (LVEF) \\<50% at Screening\n7. Systemic arterial thrombotic or embolic events within 6 months prior to the first dose of study drug\n8. Systemic venous thrombotic events within 1 month prior to the first dose of study drug\n9. Malabsorption syndrome\n10. Bone disease that requires ongoing treatment or has required treatment.\n11. Major surgery within 4 weeks of the first dose of study drug. All surgical wounds must be healed and free of infection or dehiscence before the first dose of the study drug.\n12. Any other clinically significant comorbidities.\n13. For participants receiving DCC-3116 and trametinib combination or DCC-3116 and binimetinib combination: previous treatment with trametinib or binimetinib that resulted in treatment discontinuation due to intolerability as a result of an adverse event (AE) that was considered related to trametinib or binimetinib.\n14. For participants receiving DCC-3116 and sotorasib combination in Dose Escalation Part 1: previous treatment with sotorasib that resulted in treatment discontinuation due to intolerability as a result of an adverse event (AE) that was considered related to sotorasib.\n15. For participants receiving DCC-3116 and sotorasib combination: Use of proton pump inhibitors (PPIs) and H2 receptor antagonists that cannot be discontinued 3 days prior to the start of study drug administration.\n16. Known allergy or hypersensitivity to any component of the investigational drug products.\n17. Known human immunodeficiency virus unless the following requirements are met:\n\n    1. CD4 count \\>350/\u00b5L\n    2. No AIDS-defining opportunistic infection in the last 12 months\n    3. Stable anti-retroviral regimen with medications that are not prohibited by the protocol for at least 4 weeks with HIV viral load less than 400 copies/mL prior to enrollment.\n18. Known active hepatitis B, active hepatitis C infection or if the participant is taking medications that are prohibited per protocol.\n19. If female, the participant is pregnant or lactating.\n20. Ongoing participation in an interventional study.\n21. For participants receiving DCC-3116 and binimetinib combination: Known Gilbert's syndrome",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Clinical Team",
                    "role": "CONTACT",
                    "phone": "833-432-2237",
                    "email": "clinicaltrials@deciphera.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Clinical Team",
                    "affiliation": "Deciphera Pharmaceuticals LLC",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Massachusetts General Hospital",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02114",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Colin Weekes, MD, PhD",
                            "role": "CONTACT",
                            "phone": "617-726-4000",
                            "email": "cdweekes@mgh.harvard.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Rutgers Cancer Institute",
                    "status": "RECRUITING",
                    "city": "New Brunswick",
                    "state": "New Jersey",
                    "zip": "08901",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Udochukwu (Obi) Ihuoma",
                            "role": "CONTACT",
                            "phone": "732-515-1638",
                            "email": "ui13@cinj.rutgers.edu"
                        },
                        {
                            "name": "Demmie Aguilar",
                            "role": "CONTACT",
                            "phone": "732-235-8055",
                            "email": "da572@cinj.rutgers.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.48622,
                        "lon": -74.45182
                    }
                },
                {
                    "facility": "Laura & Isaac Perlmutter Cancer Center at NYU Langone Health",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10016",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Janice Mehnert, MD",
                            "role": "CONTACT",
                            "phone": "212-731-5431",
                            "email": "janice.mehnert@nyulangone.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Oregon Health and Science University",
                    "status": "RECRUITING",
                    "city": "Portland",
                    "state": "Oregon",
                    "zip": "97239",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Laurie Oliveira",
                            "role": "CONTACT",
                            "phone": "503-418-9628",
                            "email": "oliveirl@ohsu.edu"
                        },
                        {
                            "name": "Vicki Abtin",
                            "role": "CONTACT",
                            "phone": "503-494-6542",
                            "email": "abtin@ohsu.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 45.52345,
                        "lon": -122.67621
                    }
                },
                {
                    "facility": "Hospital of the University of Pennsylvania",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19104",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Ravi Amaravadi, MD",
                            "role": "CONTACT",
                            "phone": "215-796-5159",
                            "email": "ravi.amaravadi@uphs.upenn.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                },
                {
                    "facility": "NEXT Oncology",
                    "status": "RECRUITING",
                    "city": "Austin",
                    "state": "Texas",
                    "zip": "78758",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Dr. Andrae Vandross",
                            "role": "CONTACT",
                            "phone": "737-610-5200",
                            "email": "avandross@nextoncology.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 30.26715,
                        "lon": -97.74306
                    }
                },
                {
                    "facility": "The University of Texas MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Ly Nguyen",
                            "role": "CONTACT",
                            "phone": "713-563-2169",
                            "email": "LMNguyen1@mdanderson.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "NEXT Oncology",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78229",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Cheryl Merendon",
                            "role": "CONTACT",
                            "phone": "210-580-9500",
                            "email": "cmerendon@nextoncology.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                },
                {
                    "facility": "University of Wisconsin Clinical Science Center",
                    "status": "RECRUITING",
                    "city": "Madison",
                    "state": "Wisconsin",
                    "zip": "53792",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "UW Carbone Cancer Center - Cancer Connect",
                            "role": "CONTACT",
                            "phone": "800-622-8922",
                            "email": "cancerconnect@uwcarbone.wisc.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.07305,
                        "lon": -89.40123
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5546",
                    "name": "Carcinoma, Non-Small-Cell Lung",
                    "relevance": "LOW"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000560077",
                    "term": "Trametinib"
                },
                {
                    "id": "C000706028",
                    "term": "Sotorasib"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000047428",
                    "term": "Protein Kinase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                },
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M96444",
                    "name": "Sotorasib",
                    "asFound": "Retinal Vein",
                    "relevance": "HIGH"
                },
                {
                    "id": "M218495",
                    "name": "Trametinib",
                    "asFound": "Surgery:",
                    "relevance": "HIGH"
                },
                {
                    "id": "M25820",
                    "name": "Protein Kinase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}